( NASDAQ-NMS:NBIX )

News from Neurocrine Biosciences, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 09, 2018, 16:01 ET Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Bank of America Merrill Lynch 2018 Healthcare Conference at 8:40 a.m. PT (11:40...


May 08, 2018, 14:00 ET Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced new data from RE-KINECT, the largest real-world screening study to date of patients...


May 02, 2018, 16:14 ET Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual Meeting

Neurocrine Biosciences Inc. (NASDAQ: NBIX) today announced that it will present new data from RE-KINECT, the largest real-world screening study to...


Apr 30, 2018, 16:01 ET Neurocrine Biosciences Reports First Quarter 2018 Financial Results

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the first quarter 2018, and provided an update on the launch...


Apr 25, 2018, 18:56 ET Neurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug...


Apr 23, 2018, 16:01 ET Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2018 Financial Results

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report first quarter financial results after the Nasdaq market closes on...


Apr 18, 2018, 16:01 ET Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new data for once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and...


Mar 07, 2018, 13:15 ET Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman, CEO of Neurocrine Biosciences, will present at the following...


Feb 14, 2018, 16:01 ET Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinical Trial Data

Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that...


Feb 13, 2018, 16:01 ET Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the fourth quarter and year-end of 2017, and provided an...


Feb 08, 2018, 13:15 ET Neurocrine Biosciences to Present at the Leerink Partners 7th Annual Global Healthcare Conference

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Leerink Partners 7th Annual Global Healthcare Conference at 11:30 a.m. ET on...


Feb 06, 2018, 13:15 ET Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial Results

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2017 financial results after the Nasdaq...


Jan 07, 2018, 13:01 ET Neurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer

Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that...


Jan 07, 2018, 13:00 ET Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced an update on its business performance, including preliminary sales results for 2017 and...


Jan 02, 2018, 16:01 ET Neurocrine Biosciences to Present at the 36th Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 36th Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT (6:00 p.m. ET) on...


Dec 07, 2017, 13:15 ET Neurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference at 11:00...


Dec 04, 2017, 16:01 ET Neurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new long-term data from the KINECT 4 Phase III open-label study demonstrate that...


Nov 29, 2017, 16:01 ET Neurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual Meeting

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new long-term data from the open-label KINECT 4 Phase III study of INGREZZA®...


Nov 21, 2017, 13:15 ET Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 29th Annual Piper Jaffray Healthcare Conference at 12:00 p.m. ET on Tuesday, Nov....


Nov 20, 2017, 16:01 ET Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer

Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that...


Nov 14, 2017, 13:34 ET Neurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the full manuscript of the long-term safety and efficacy data from the blinded...


Nov 09, 2017, 16:01 ET INGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Award from Prestigious California Life Sciences Association

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that INGREZZA® (valbenazine) capsules, the first FDA approved product indicated for the...


Nov 08, 2017, 13:15 ET Neurocrine Biosciences to Present at the Jefferies 2017 London Healthcare Conference

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2017 London Healthcare Conference at 11:20 a.m. GMT (6:20 a.m. ET) on...


Nov 07, 2017, 16:01 ET Neurocrine to Present Data on the Patient Impact of Tardive Dyskinesia from the RE-KINECT Study at the 2017 Neuroscience Education Institute Congress

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that data for INGREZZA® (valbenazine) capsules, the first FDA approved treatment for...


Nov 01, 2017, 16:01 ET Neurocrine Biosciences Reports Third Quarter 2017 Results

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2017. "We are very pleased...